Seelos Therapeutics, Inc. (NASDAQ:SEEL)’s stock price was down 14.4% during trading on Thursday . The stock traded as low as $1.65 and last traded at $1.72. Approximately 2,804,899 shares were traded during trading, an increase of 117% from the average daily volume of 1,294,935 shares. The stock had previously closed at $2.01.
A number of brokerages have weighed in on SEEL. Zacks Investment Research upgraded Seelos Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research note on Saturday, October 24th. Roth Capital restated a “buy” rating and set a $12.00 price objective on shares of Seelos Therapeutics in a research note on Monday, September 28th.
The company has a quick ratio of 2.09, a current ratio of 2.09 and a debt-to-equity ratio of 0.04. The stock has a 50 day moving average price of $1.00 and a 200 day moving average price of $0.97.
An institutional investor recently bought a new position in Seelos Therapeutics stock. Virtu Financial LLC bought a new stake in Seelos Therapeutics, Inc. (NASDAQ:SEEL) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 96,359 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned approximately 0.21% of Seelos Therapeutics at the end of the most recent reporting period. Institutional investors own 9.96% of the company’s stock.
Seelos Therapeutics Company Profile (NASDAQ:SEEL)
Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; SLS-005, a protein stabilizer for the treatment of Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD).
See Also: Discover Your Risk Tolerance